TITLE

Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma

AUTHOR(S)
Palumbo, A.; Davies, F.; Kropff, M.; Bladé, J.; Delforge, M.; Costa, F. Leal Da; Garcia Sanz, R.; Schey, S.; Facon, T.; Morgan, G.; Moreau, P.
PUB. DATE
August 2010
SOURCE
Annals of Hematology;Aug2010, Vol. 89 Issue 8, p803
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Thalidomide has received approval from the European Agency for the Evaluation of Medicinal Products for the treatment of newly diagnosed multiple myeloma (MM) patients older than 65 years or ineligible for transplant. The results of five phase III trials assessing thalidomide in combination with melphalan and prednisone (MPT) have demonstrated significantly improved response rates compared with melphalan and prednisone (MP) alone. Additionally, two of these studies showed that survival was extended by approximately 18 months in patients treated with MPT compared with MP alone. Thalidomide, in combination with MP, is associated with adverse events (AEs) including peripheral neuropathy and venous thromboembolism. In order to optimize the efficacy of MPT, a good awareness of these AEs is imperative. This manuscript outlines both evidence- and consensus-based recommendations discussed by a panel of experts, to provide a practical guide for physicians addressing the effective management of newly diagnosed, transplant-ineligible MM patients receiving thalidomide therapy.
ACCESSION #
51521851

 

Related Articles

  • Lenalidomide in Myelodysplastic Syndrome and Multiple Myeloma. Shah, Sachin R.; Tran, Thu M. // Drugs;2007, Vol. 67 Issue 13, p1869 

    The use of thalidomide is limited by adverse effects of sedation, constipation, neuropathy and thromboembolism. In order to discover more potent and less toxic immunomodulators than thalidomide, its chemical structure was modified and lenalidomide was formed. Lenalidomide is approved by the US...

  • Thalidomide-induced severe hepatotoxicity. Dabak, Vrushali; Kuriakose, Philip // Cancer Chemotherapy & Pharmacology;Mar2009, Vol. 63 Issue 4, p583 

    The article focuses on the impact of thalidomide, the drug of choice for erythema nodosum leprosum on medicine. Thalidomide was introduced as a sedative agent and was found to alleviate symptoms of morning sickness. It was approved by the Food and Drug Administration (FDA) for use in combination...

  • Effects of prednisone on the International Normalized Ratio. Stading, Julie A. // American Journal of Health-System Pharmacy;12/1/2006, Vol. 63 Issue 23, p2354 

    Purpose. The effects of prednisone on the International Normalized Ratio (INR) values of a patient were examined. Summary. A 66-year-old white man with a history of multiple myeloma was treated in an ambulatory care anticoagulation clinic for deep vein thrombosis. His INR values were normal...

  • Traitement du myélome multiple. Coiteux, V.; Tricot, S.; Wemeau, M.; Facon, T. // Oncologie;mai2006, Vol. 8 Issue 4, p357 

    The past twenty years have brought continuous progress in the management of care for patients suffering from multiple myeloma (MM). Intensive treatment by autologous peripheral blood stem cell transplantation is now a reference treatment for patients under the age of 65. Since 1999, three new...

  • New therapies in multiple myeloma. Merchionne, F.; Perosa, F.; Dammacco, F. // Clinical & Experimental Medicine;Sep2007, Vol. 7 Issue 3, p83 

    The melphalan-prednisone regimen has been considered as standard therapy for patients with multiple myeloma (MM) for many years. Recently, high-dose chemotherapy with stem-cell support has extended progression-free survival and increased overall survival, and it is now considered conventional...

  • Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Kapoor, P.; Rajkumar, S. V.; Dispenzieri, A.; Gertz, M. A.; Lacy, M. Q.; Dingli, D.; Mikhael, J. R.; Roy, V.; Kyle, R. A.; Greipp, P. R.; Kumar, S.; Mandrekar, S. J. // Leukemia (08876924);Apr2011, Vol. 25 Issue 4, p689 

    Trials comparing efficacy of melphalan prednisone (MP) with MP plus thalidomide in transplant ineligible, elderly patients with multiple myeloma have provided conflicting evidence. Although there is agreement regarding improved response rates (RRs) and higher toxicity with the addition of...

  • Anti-angiogenic effects of thalidomide: expression of apoptosis-inducible active-caspase-3 in a three-dimensional collagen gel culture of aorta. Fujita, Keiko; Asami, Yoshiko; Tanaka, Kayoko; Akita, Masumi; Merker, Hans-Joachim // Histochemistry & Cell Biology;Jul2004, Vol. 122 Issue 1, p27 

    The anti-angiogenic properties of thalidomide have led to the use of the agent as a remedy for multiple myeloma. Nevertheless, the anti-angiogenic moiety of thalidomide remains unidentified. In this study we examined the anti-angiogenic effects of thalidomide in an in vitro model using a...

  • Thalidomide as an Antiangiogenic Drug in the Treatment of Multiple Myeloma. Ribatti, Domenico; Vacca, Angelo // Letters in Drug Design & Discovery;Apr2004, Vol. 1 Issue 2, p135 

    Experimental studies have demonstrated that thalidomide, a drug developed as a sedative, has antitumoral properties. Its broad spectrum of actions besides its antiangiogenic potential, includes immunomodulatory properties, antiinflammatory actions and direct effect on tumor cells and their...

  • Timeline: The evolution of thalidomide and its IMiD derivatives as anticancer agents. Bartlett, J. Blake; Dredge, Keith; Dalgleish, Angus G. // Nature Reviews Cancer;Apr2004, Vol. 4 Issue 4, p314 

    Thalidomide was originally used to treat morning sickness, but was banned in the 1960s for causing serious congenital birth defects. Remarkably, thalidomide was subsequently discovered to have anti-inflammatory and anti-angiogenic properties, and was identified as an effective treatment for...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics